DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
semaglutide (Ozempic) to tirzepatide (Mounjaro). Dose mapping, washout, expected side effects, and the editorial verdict.
Type 2 diabetes patients with inadequate A1C response on Ozempic. Tirzepatide produced lower A1C and greater weight loss than semaglutide in SURPASS-2 (May 2022, NEJM). Both are diabetes-indicated, so insurance hurdles are minimal.
No washout. Start at Mounjaro 2.5 mg next injection day. Hold metformin / sulfonylurea adjustments until first endo follow-up.
For T2D patients who plateau on Ozempic, Mounjaro is the most evidence-backed next step.
GI side effects reset. Watch for hypoglycemia if you are on sulfonylurea or basal insulin; tirzepatide is more potent than semaglutide and dose-equivalent insulin reduction is often required.
Both T2D-indicated. PA usually granted with A1C ≥ 7.0 or documented Ozempic intolerance. No formulary gymnastics.
Manufacturer cards comparable. Without insurance, both retail $900-1,100/mo.
If A1C is well-controlled and weight is stable on Ozempic, the marginal benefit of switching is small. Discuss with your endocrinologist before adding side-effect burden for incremental improvement.
Editorial summary, not medical advice. Drug switches should be coordinated with your prescriber. Dose conversions reflect typical practice; your prescriber may adjust based on tolerance, comorbidities, or interactions.